MPS2 improves on the foundational technology of MPS, a test included in the National Comprehensive Cancer Network® (NCCN®) guidelines related to prostate cancer diagnosis.
The MPS2 algorithm has been developed to optimize accuracy. For biopsy naïve patients, MPS2 is a standalone biomarker test.
For patients with a prior negative biopsy, clinical factors most relevant to repeat biopsy patients have been included in the algorithm. These patients present a unique clinical challenge. We offer proven performance data for this population.1
The specificity of the T2:ERG fusion gene, the foundation of MPS2, with a supporting array of 17 other genetic biomarkers that characterize prostate cancer, offers population-specific results with next generation accuracy.